Insulet Future Growth
Future criteria checks 4/6
Insulet is forecast to grow earnings and revenue by 17.5% and 13.8% per annum respectively. EPS is expected to grow by 15.9% per annum. Return on equity is forecast to be 21.4% in 3 years.
Key information
17.5%
Earnings growth rate
15.9%
EPS growth rate
Medical Equipment earnings growth | 17.5% |
Revenue growth rate | 13.8% |
Future return on equity | 21.4% |
Analyst coverage | Good |
Last updated | 02 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,731 | 368 | 383 | 484 | 12 |
12/31/2025 | 2,323 | 279 | 270 | 385 | 20 |
12/31/2024 | 1,960 | 214 | 275 | 415 | 20 |
12/31/2023 | 1,697 | 206 | 37 | 146 | N/A |
9/30/2023 | 1,557 | 120 | -15 | 151 | N/A |
6/30/2023 | 1,465 | 63 | -26 | 152 | N/A |
3/31/2023 | 1,368 | 1 | -45 | 133 | N/A |
12/31/2022 | 1,305 | 5 | -38 | 119 | N/A |
9/30/2022 | 1,243 | 17 | -63 | 43 | N/A |
6/30/2022 | 1,178 | 35 | -141 | -40 | N/A |
3/31/2022 | 1,142 | 45 | -152 | -47 | N/A |
12/31/2021 | 1,099 | 17 | -191 | -68 | N/A |
9/30/2021 | 1,037 | -29 | -199 | -26 | N/A |
6/30/2021 | 996 | -30 | -126 | 44 | N/A |
3/31/2021 | 959 | 9 | -120 | 53 | N/A |
12/31/2020 | 904 | 7 | -82 | 84 | N/A |
9/30/2020 | 868 | 29 | -15 | 114 | N/A |
6/30/2020 | 826 | 18 | -25 | 101 | N/A |
3/31/2020 | 777 | 5 | -65 | 88 | N/A |
12/31/2019 | 738 | 12 | -72 | 98 | N/A |
9/30/2019 | 694 | 17 | -74 | 82 | N/A |
6/30/2019 | 653 | 17 | -103 | 67 | N/A |
3/31/2019 | 600 | 14 | -126 | 47 | N/A |
12/31/2018 | 564 | 3 | -126 | 36 | N/A |
9/30/2018 | 529 | -13 | -130 | 27 | N/A |
6/30/2018 | 500 | -17 | -93 | 35 | N/A |
3/31/2018 | 486 | -23 | -28 | 59 | N/A |
12/31/2017 | 464 | -27 | -36 | 41 | N/A |
9/30/2017 | 437 | -29 | N/A | 39 | N/A |
6/30/2017 | 410 | -30 | N/A | 19 | N/A |
3/31/2017 | 387 | -26 | N/A | 5 | N/A |
12/31/2016 | 367 | -27 | N/A | 16 | N/A |
9/30/2016 | 347 | -34 | N/A | -23 | N/A |
6/30/2016 | 324 | -49 | N/A | -17 | N/A |
3/31/2016 | 297 | -62 | N/A | -20 | N/A |
12/31/2015 | 264 | -62 | N/A | -13 | N/A |
9/30/2015 | 253 | -51 | N/A | 11 | N/A |
6/30/2015 | 256 | -44 | N/A | 7 | N/A |
3/31/2015 | 268 | -56 | N/A | 6 | N/A |
12/31/2014 | 231 | -48 | N/A | 9 | N/A |
9/30/2014 | 285 | -49 | N/A | 1 | N/A |
6/30/2014 | 271 | -59 | N/A | 0 | N/A |
3/31/2014 | 259 | -40 | N/A | 4 | N/A |
12/31/2013 | 247 | -45 | N/A | 3 | N/A |
9/30/2013 | 236 | -53 | N/A | 1 | N/A |
6/30/2013 | 230 | -44 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: P2OD34's forecast earnings growth (17.5% per year) is above the savings rate (9.9%).
Earnings vs Market: P2OD34's earnings (17.5% per year) are forecast to grow faster than the BR market (13.9% per year).
High Growth Earnings: P2OD34's earnings are forecast to grow, but not significantly.
Revenue vs Market: P2OD34's revenue (13.8% per year) is forecast to grow faster than the BR market (7.2% per year).
High Growth Revenue: P2OD34's revenue (13.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: P2OD34's Return on Equity is forecast to be high in 3 years time (21.4%)